<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380935</url>
  </required_header>
  <id_info>
    <org_study_id>convalescent plasma RSCM-FKUI</org_study_id>
    <nct_id>NCT04380935</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome</brief_title>
  <official_title>Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corona virus disease 2019 (COVID-19) has been declared as a Pandemic by the World Health
      Organization (WHO). According to WHO report on March 31st 2020, globally COVID-19 have
      infected over 750,000 people and caused over 36,000 deaths with case fatality rate of 4.85%.
      In Indonesia, COVID-19 have infected 1,414 people and caused 122 deaths with case fatality
      rate of 8.63%. In severe cases, COVID-19 causes complications, such as acute respiratory
      distress syndrome (ARDS), sepsis, septic shock, and multi-organ dysfunction syndrome (MODS),
      where age and comorbid illnesses as a major factor to these complications. Up to this point
      there are several promising therapies for COVID-19 but is not yet recommended and in need of
      further research. The use of convalescent plasma has been approved by the US Food and Drug
      Administration (FDA) through the scheme of emergency investigational new drug (eIND). This
      method has been used as the treatment in several outbreak or plague cases over the years,
      such as the flu epidemic in 1918, polio, measles, mumps, SARS (severe acute respiratory
      syndrome), EVD (Ebola virus disease) and MERS (middle-eastern respiratory syndrome) and this
      treatment shows better outcome. Several case report on the use of convalescent plasma for
      COVID-19 patients with ARDS and mechanical ventilation has been reported and shows promising
      outcome. Nevertheless, larger and multicenter research need to be done to assess and evaluate
      the effectiveness and safety of convalescent plasma therapy on for COVID-19 patients with
      ARDS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Mean length of stay in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Mean duration of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature (degree in Celsius)</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAO2/FIO2 ratio</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP) in mg/L</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer in ng/mL</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin in ng/mL</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6) in pg/mL</measure>
    <time_frame>Day 1, 3, 5, and 7 after administration of therapy</time_frame>
    <description>Mean change from baseline using time series analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic/ anaphylaxis transfusion reaction</measure>
    <time_frame>24 hours post-transfusion</time_frame>
    <description>Number of participants with allergic/ anaphylaxis transfusion reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemolytic transfusion reaction</measure>
    <time_frame>24 hours post-transfusion</time_frame>
    <description>Number of participants with Hemolytic transfusion reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion Related Acute Lung Injury</measure>
    <time_frame>24 hours post-transfusion</time_frame>
    <description>Number of participants with Transfusion Related Acute Lung Injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion associated Circulatory Overload</measure>
    <time_frame>24 hours post-transfusion</time_frame>
    <description>Number of participants with Transfusion associated Circulatory Overload</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>convalescent plasma and standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Convalescent plasma of recovered COVID-19 patients (donor)</description>
    <arm_group_label>convalescent plasma and standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>According to national or hospital guidelines &quot;COVID-19 Management Protocol&quot;</description>
    <arm_group_label>convalescent plasma and standard of care</arm_group_label>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged more than equal to 18 years.

          -  COVID-19 confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR)

          -  Having severe pneumonia.

          -  PAO2 / FIO2 &lt;300.

        Exclusion Criteria:

          -  Contraindication to blood transfusions (fluid overload, history of anaphylaxis of
             blood products)

          -  Multiple and severe organ failure, hemodynamically unstable

          -  Other uncontrolled infections

          -  Disseminated intravascular coagulation (DIC) which requires a replacement factor/FFP

          -  Hemodialysis patients or CRRT (continuous renal replacement therapy)

          -  Active intracranial bleeding

          -  Significant myocardial ischemia

          -  Receiving tocilizumab treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andri MT Lubis, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Sinto, MD</last_name>
    <phone>+628158835432</phone>
    <email>rsinto@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sinto, MD</last_name>
      <phone>+628158835432</phone>
      <email>rsinto@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Andri MT Lubis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sinto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elida Marpaung, MD, MBiomed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cosphiadi Irawan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lugyanti Sukrisman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siti Rizny F Saldi, Pharm, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Djauhari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Carolus Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Sinto, MD</last_name>
      <phone>+628158835432</phone>
      <email>rsinto@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ciputra Hospital CitraRaya</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>15710</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santi Gultom, MD</last_name>
      <phone>+6282120683216</phone>
      <email>santich.gultom@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200331-sitrep-71-covid-19.pdf?sfvrsn=4360e92b_4</url>
    <description>Coronavirus disease 2019 Situation Report</description>
  </link>
  <link>
    <url>https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</url>
    <description>Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected.</description>
  </link>
  <link>
    <url>https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.11.2000230</url>
    <description>Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020.</description>
  </link>
  <link>
    <url>https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.11.2000266</url>
    <description>Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020</description>
  </link>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 May;46(5):854-887. doi: 10.1007/s00134-020-06022-5. Epub 2020 Mar 28.</citation>
    <PMID>32222812</PMID>
  </reference>
  <reference>
    <citation>Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020 Mar 26;368:m1256. doi: 10.1136/bmj.m1256.</citation>
    <PMID>32217555</PMID>
  </reference>
  <reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </reference>
  <reference>
    <citation>van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N; Ebola-Tx Consortium. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812.</citation>
    <PMID>26735992</PMID>
  </reference>
  <reference>
    <citation>Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0. Review.</citation>
    <PMID>32169119</PMID>
  </reference>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, Yan B, Shi ZL, Zhou P. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020 Feb 17;9(1):386-389. doi: 10.1080/22221751.2020.1729071. eCollection 2020.</citation>
    <PMID>32065057</PMID>
  </reference>
  <reference>
    <citation>Rawal G, Yadav S, Kumar R. Acute Respiratory Distress Syndrome: An Update and Review. J Transl Int Med. 2018 Jun 26;6(2):74-77. doi: 10.1515/jtim-2016-0012. eCollection 2018 Jun.</citation>
    <PMID>29984201</PMID>
  </reference>
  <reference>
    <citation>Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, Chee N, Connolly B, Dark P, Finney S, Salam A, Silversides J, Tarmey N, Wise MP, Baudouin SV. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019 May 24;6(1):e000420. doi: 10.1136/bmjresp-2019-000420. eCollection 2019.</citation>
    <PMID>31258917</PMID>
  </reference>
  <reference>
    <citation>ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.</citation>
    <PMID>22797452</PMID>
  </reference>
  <reference>
    <citation>Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, Novack V, Mutumwinka M, Talmor DS, Fowler RA. Hospital Incidence and Outcomes of the Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin Definition. Am J Respir Crit Care Med. 2016 Jan 1;193(1):52-9. doi: 10.1164/rccm.201503-0584OC.</citation>
    <PMID>26352116</PMID>
  </reference>
  <reference>
    <citation>Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJM, Leo YS, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Apr 21;323(15):1488-1494. doi: 10.1001/jama.2020.3204.</citation>
    <PMID>32125362</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.</citation>
    <PMID>32161940</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.</citation>
    <PMID>32085846</PMID>
  </reference>
  <reference>
    <citation>To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1. Epub 2020 Mar 23.</citation>
    <PMID>32213337</PMID>
  </reference>
  <reference>
    <citation>Roback JD, Guarner J. Convalescent Plasma to Treat COVID-19: Possibilities and Challenges. JAMA. 2020 Apr 28;323(16):1561-1562. doi: 10.1001/jama.2020.4940.</citation>
    <PMID>32219429</PMID>
  </reference>
  <reference>
    <citation>Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. Review.</citation>
    <PMID>25030060</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Andri Maruli Tua Lubis</investigator_full_name>
    <investigator_title>Head of Research Division RSCM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

